Asarina Pharma AB
A biotechnology company in liquidation, formerly focused on neurosteroid therapies.
ASAP | ST
Overview
Corporate Details
- ISIN(s):
- SE0011641794
- LEI:
- 549300PP1GKOHKYQ6K97
- Country:
- Sweden
- Address:
- Fogdevreten 2, 171 65 Solna
- Website:
- https://asarinapharma.com/
Description
Asarina Pharma was a biotechnology company focused on developing Sepranolone, a therapy for disorders related to the neurosteroid allopregnanolone. The company's research targeted conditions including premenstrual dysphoric disorder (PMDD), Tourette syndrome, and other stress- and compulsion-driven disorders. Following the sale of its primary asset, Sepranolone, to Relmada Therapeutics, the company has entered into liquidation.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Asarina Pharma AB filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Asarina Pharma AB
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Asarina Pharma AB via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
